Infinity Licenses Intellikine Compounds | July 19, 2010 Issue - Vol. 88 Issue 29 | Chemical & Engineering News
Volume 88 Issue 29 | p. 19 | Concentrates
Issue Date: July 19, 2010

Infinity Licenses Intellikine Compounds

Department: Business
Keywords: phosphinositide, license, pharmaceuticals

Infinity Pharmaceuticals, a small-molecule drug firm in Cambridge, Mass., will obtain development and commercialization rights to Intellikine’s portfolio of inhibitors of the δ and γ isoforms of phosphoinositide-3-kinase (PI3K). They include INK1197, a cancer therapy that is expected to enter the clinic next year. Under the license agreement, Intellikine will receive $13.5 million in initial payments, development payments of up to $25 million, and commercialization payments of up to $450 million.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment